Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Bottini · SciRah

Researcher profile · Semantic Scholar

A. Bottini

Share profile

A. Bottini — researcher profile on SciRah

h-index: 39
Works: 226
Citations: 6,432

Most-cited papers

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
F. Bidard, D. Peeters, T. Fehm, F. Nolè +39 more
2014The Lancet Oncology788 citations
Semantic Scholar
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
V. Guarneri, A. Frassoldati, A. Bottini, K. Cagossi +17 more
2012Journal of Clinical Oncology341 citations Open access
Semantic Scholar
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
M. Milani, T. Rzymski, H. Mellor, Luke R. G. Pike +3 more
2009Cancer Research321 citations Open access
Semantic Scholar
Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
A. Berruti, V. Amoroso, F. Gallo, V. Bertaglia +6 more
2014Journal of Clinical Oncology238 citations
Semantic Scholar
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial
C. Tinterri, D. Gentile, W. Gatzemeier, A. Sagona +61 more
2022Annals of Surgical Oncology150 citations Open access
Semantic Scholar
Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients
D. Generali, Gaynor J. Bates, A. Berruti, M. Brizzi +11 more
2009Clinical Cancer Research144 citations Open access
Semantic Scholar
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
D. Generali, F. Buffa, A. Berruti, M. Brizzi +11 more
2009Journal of Clinical Oncology116 citations Open access
Semantic Scholar
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
A. Cavazzoni, M. Bonelli, C. Fumarola, S. La Monica +12 more
2012Cancer Letters90 citations
Semantic Scholar
Gene expression profiling in breast cancer: a clinical perspective.
G. Arpino, D. Generali, A. Sapino, Lucia Del Matro +15 more
2013Breast89 citations Open access
Semantic Scholar
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility
A. Ravelli, G. Roviello, D. Cretella, A. Cavazzoni +10 more
2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine88 citations Open access
Semantic Scholar
Mucinous breast cancer: A narrative review of the literature and a retrospective tertiary single-centre analysis
E. Marrazzo, F. Frusone, Flavio Milana, A. Sagona +11 more
2019Breast80 citations Open access
Semantic Scholar
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).
V. Amoroso, D. Generali, T. Buchholz, M. Cristofanilli +29 more
2011Journal of the National Cancer Institute. Monographs77 citations Open access
Semantic Scholar
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
G. Allevi, C. Strina, D. Andreis, V. Zanoni +14 more
2013British Journal of Cancer71 citations Open access
Semantic Scholar
“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?
Nadia Margariti, S. Fox, A. Bottini, D. Generali
2011Breast Cancer Research and Treatment62 citations
Semantic Scholar
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment
C. Tinterri, G. Canavese, W. Gatzemeier, E. Barbieri +59 more
2023British Journal of Surgery61 citations Open access
Semantic Scholar
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).
A. Berruti, D. Generali, M. Kaufmann, Lajos Puztai +35 more
2011Journal of the National Cancer Institute. Monographs56 citations Open access
Semantic Scholar
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
G. Roviello, S. Sigala, S. Sandhu, A. Bonetta +6 more
2016European Journal of Cancer55 citations Open access
Semantic Scholar
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
V. Guarneri, D. Generali, A. Frassoldati, F. Artioli +16 more
2014Journal of Clinical Oncology53 citations Open access
Semantic Scholar
Down-Regulation of Phosphatidylinositol 3′-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer
D. Generali, S. Fox, M. Brizzi, G. Allevi +12 more
2008Clinical Cancer Research52 citations Open access
Semantic Scholar
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights
A. Ravelli, J. Reuben, F. Lanza, S. Anfossi +12 more
2015Tumor Biology44 citations
Semantic Scholar
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes
E. Ribeiro, M. Ganzinelli, D. Andreis, R. Bertoni +9 more
2013PLoS ONE43 citations Open access
Semantic Scholar
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment
D. Generali, F. Buffa, S. Deb, M. Cummings +11 more
2014British Journal of Cancer42 citations Open access
Semantic Scholar
Synergistic activity of letrozole and sorafenib on breast cancer cells
M. Bonelli, C. Fumarola, R. Alfieri, S. La Monica +12 more
2010Breast Cancer Research and Treatment40 citations
Semantic Scholar
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
T. Triulzi, L. De Cecco, M. Sandri, A. Prat +11 more
2015OncoTarget39 citations Open access
Semantic Scholar
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials.
G. Roviello, S. Sigala, R. Danesi, M. Del Re +5 more
2016Critical reviews in oncology/hematology37 citations Open access
Semantic Scholar
Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions.
A. Berruti, M. Brizzi, D. Generali, M. Ardine +3 more
2008The Oncologist37 citations Open access
Semantic Scholar
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis.
R. Petrioli, G. Roviello, L. Zanotti, F. Roviello +6 more
2016Critical reviews in oncology/hematology34 citations Open access
Semantic Scholar
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
L. Bazzola, C. Foroni, D. Andreis, V. Zanoni +19 more
2014British Journal of Cancer31 citations Open access
Semantic Scholar
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
F. Montemurro, S. Redana, G. Viale, G. Sanna +15 more
2008Clinical Breast Cancer31 citations
Semantic Scholar
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
D. Generali, A. Dovio, M. Tampellini, M. Tucci +11 more
2008British Journal of Cancer29 citations Open access
Semantic Scholar
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
S. Fox, D. Generali, A. Berruti, M. Brizzi +10 more
2011Breast Cancer Research28 citations Open access
Semantic Scholar
Neo-Adjuvant Chemotherapy in Luminal, Node Positive Breast Cancer: Characteristics, Treatment and Oncological Outcomes: A Single Center's Experience.
E. Barbieri, D. Gentile, A. Bottini, A. Sagona +4 more
2021European Journal of Breast Health27 citations Open access
Semantic Scholar
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer
D. Generali, S. Venturini, C. Rognoni, Oriana Ciani +5 more
2015Breast Cancer Research and Treatment27 citations
Semantic Scholar
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer
F. Marmé, W. Werft, A. Walter, Sascha Keller +24 more
2012Breast Cancer Research and Treatment24 citations
Semantic Scholar
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use
L. Zanotti, A. Bottini, Camillo Rossi, D. Generali +1 more
2014Tumor Biology23 citations
Semantic Scholar
Metastases from Occult Breast Cancer: A Case Report of Carcinoma of Unknown Primary Syndrome
E. Barbieri, C. Anghelone, D. Gentile, C. La Raja +2 more
2020Case Reports in Oncology21 citations Open access
Semantic Scholar
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy
M. Koukourakis, A. Giatromanolaki, A. Bottini, M. Cappelletti +12 more
2014British Journal of Cancer20 citations Open access
Semantic Scholar
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
M. Campiglio, R. Bufalino, M. Sandri, E. Ferri +18 more
2011Breast Cancer Research and Treatment20 citations Open access
Semantic Scholar
No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.
G. Roviello, L. Zanotti, M. Cappelletti, A. Gobbi +3 more
2016Clinical Lung Cancer19 citations Open access
Semantic Scholar
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
A. Schneeweiss, F. Marmé, Amparo Ruiz, A. Manikhas +6 more
2011Annals of Oncology19 citations Open access
Semantic Scholar
Immunomodulation of FOXP 3 + Regulatory TCells by theAromatase Inhibitor Letrozole in Breast Cancer Patients
D. Generali, Gaynor J. Bates, A. Berruti, M. Brizzi +11 more
200916 citations
Semantic Scholar
Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis
C. Tinterri, S. Di Maria Grimaldi, A. Sagona, E. Barbieri +4 more
2023Cancers15 citations Open access
Semantic Scholar
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy”
C. Foroni, M. Milan, C. Strina, M. Cappelletti +18 more
2014Breast Cancer Research and Treatment14 citations
Semantic Scholar
Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
M. Martino, A. Bottini, G. Rosti, D. Generali +6 more
2012Expert Opinion on Biological Therapy14 citations
Semantic Scholar
Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer
M. Milani, S. Venturini, S. Bonardi, G. Allevi +13 more
2017OncoTarget13 citations Open access
Semantic Scholar
Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity
A. Ravelli, J. Reuben, F. Lanza, S. Anfossi +9 more
2015Expert Review of Anticancer Therapy13 citations
Semantic Scholar
Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?
F. Bedussi, A. Bottini, M. Memo, S. Fox +2 more
2014Expert opinion on therapeutic targets13 citations
Semantic Scholar
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
T. Mele, D. Generali, S. Fox, M. Brizzi +10 more
2010Breast Cancer Research and Treatment12 citations Open access
Semantic Scholar
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
G. Roviello, M. Milani, A. Gobbi, M. Dester +11 more
2016Future Oncology9 citations
Semantic Scholar
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
D. Generali, A. Berruti, M. Cappelletti, L. Zanotti +14 more
2015Journal of the National Cancer Institute. Monographs9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Generali×39
Invite
D. Generali — researcher profile on SciRah
S. Fox×19
Invite
S. Fox — researcher profile on SciRah
A. Harris×17
Invite
A. Harris — researcher profile on SciRah
M. Milani×16
Invite
M. Milani — researcher profile on SciRah

×16

Invite

A. Berruti — researcher profile on SciRah

M. Cappelletti×16

Invite

M. Cappelletti — researcher profile on SciRah

Invite

G. Allevi — researcher profile on SciRah

L. Dogliotti×11

Invite

L. Dogliotti — researcher profile on SciRah

Invite

L. Zanotti — researcher profile on SciRah

S. Aguggini×10

Invite

S. Aguggini — researcher profile on SciRah

Invite

S. Bonardi — researcher profile on SciRah

Invite

M. Brizzi — researcher profile on SciRah